Immunotherapy may be safe treatment method for patients with Type-1 diabetes.
Picture for symbolic purpose only. (Photo courtesy: AFP Relaxnews/ AzmanJaka/ Istock.com)
Researchers from King’s College London and Cardiff University discovered that immunotherapy using a peptide technology may potentially help to “retrain” the immune system and so slow the development of diabetes.
“It was encouraging to see that individuals who receive the therapy had less insulin to control their blood sugar levels, implying that their pancreas was functioning better,” said Colin Dayan, Professor at the Cardiff University in the united kingdom. Type-1 diabetes develops when a patient’s immune system attacks the beta cells in the pancreas.
Without treatment the amount of beta cells gradually decrease and your body no longer is able to keep normal blood glucose (blood sugar) levels.
In the study, published in the journal Science Translational Medicine, once the patients were recovered with peptides fragments of protein molecules found in cells of pancreas — they demonstrated noticeable changes in their systems’ behaviour.
“The peptide technology employed in our trial not merely appears to be safe for patients at this stage, but additionally, it has a noticeable effect in the immune system,” explained lead researcher Mark Peakman, Professor at King’s College London.
There’s currently no cure for Type-1 diabetes, which can affect big organs.
“These new findings are an exciting step in immunotherapies being used to prevent this serious illness from developing in those at high risk, or prevent it from progressing in those already diagnosed,” said Elizabeth Robertson, Director at the Diabetes UK — a charity business.
See Whole article